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Background: B cell chronic lymphocytic leukemia/lymphoma 11 A (BCL11A) is associated with human B cell
malignancy initiation. Our previous study has shown that downregulation of BCL11A mRNA by small interfering
RNA (siRNA) is capable of inducing apoptosis in the SUDHL6 cell line. To further explore the effects of BCL11A siRNA
on the enhanced cytotoxicity of a chemotherapeutic drug, we investigated the effects of BCL11A siRNA combined
with vincristine (VCR) on SUDHL6 cell proliferation and apoptosis.
Methods: Chemically synthesized BCL11A siRNA was transfected into SUDHL6 cells using the HiPerFect Transfection
Reagent in combination with VCR. Cell proliferation was measured by the CCK8 assay. The morphology of
apoptotic cells was observed with Hoechst 33258 staining. The rate of cell apoptosis was determined by
annexin V-fluorescein isothiocyanate/propidium iodide double staining using fluorescence-activated cell sorting
(FACS) analysis.
Results: After BCL11A siRNA plus VCR treatment, cell proliferation was significantly decreased in comparison
with VCR or BCL11A siRNA treatment alone and negative control siRNA plus VCR treatment (P <0.05). The
apoptotic rate of BCL11A siRNA plus VCR treated cells was significantly increased compared with BCL11A siRNA
and VCR treatment alone and negative control siRNA plus VCR treatment (P <0.05).
Conclusions: The combination of BCL11A siRNA and VCR increases apoptosis in SUDHL6 cells. Our study implies
that BCL11A siRNA in combination with VCR may be a useful approach for improving effective treatment for
B cell lymphoma.
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Diffuse large B cell lymphoma (DLBCL) is the most com-
mon type of non-Hodgkin lymphoma (NHL) [1,2]. DLBCL
is a heterogeneous disease in its morphology, immunophe-
notype, and biological behavior, and it includes subtypes
with diverse origins and gene expression profiles [1,3].
Current treatments for NHL are not optimally effective and
mainly result in relapse and resistance to chemotherapy
[4,5]. Therefore, further investigation of specific DLBCL
biomarkers, development of more targeted treatments, and
improvement of the effects of treatment are indispensable
for significantly increasing the survival of patients.* Correspondence: thedm@jnu.edu.cn; jnyangqiuli@163.com
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(BCL11) gene family members, including the BCL11A and
BCL11B, have been identified as transcriptional repressors,
which are essential for lymphoid development [6-8]. The
BCL11B gene, which is related to malignant T cell trans-
formation, plays a crucial role in the development, pro-
liferation, differentiation and subsequent survival of T cells
[9]. BCL11A has been identified on human chromosome
2p16.1 (previously mapped at 2p13) where chromosomal
abnormalities are associated with human lymphoma
[10,11]. Recently, Yin et al. suggested that BCL11A acts as
an oncogene and may contribute to leukemogenesis in
certain groups of AML patients [12]. BCL11A overexpres-
sion is primarily found in B cell lymphoma and B cell
leukemia [11,13-16]. We and others have demonstrated
the essential role of BCL11A in the proliferation and sur-
vival of B cells [8,17]. Our previous study has shown thatThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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RNA (siRNA) is capable of inducing apoptosis in B lym-
phoma cell lines (SUDHL6 and EB1) [17]. Gene expres-
sion profiling revealed that various genes related to
apoptosis and proliferation are altered during BCL11A
siRNA-mediated SUDHL6 cell apoptosis (WH and Gao
Yangjun, unpublished data).
Vincristine (VCR) is a commonly used chemothera-
peutic agent for many lymphoid malignancies, including
aggressive NHL. Depending on the therapeutic dose,
most chemotherapeutic agents have side effects. VCR
has additional peripheral neurological side effects such
as hearing changes, sensory loss, numbness, and tingling
[18]. Serious side effects in response to chemotherapeu-
tic agents led researchers to seek novel anticancer agents
with fewer side effects, and these newly explored anti-
cancer agents can be used in combination with com-
monly used chemotherapeutic agents to reduce serious
side effects [19-22]. A recent report suggested a possible
synergy between VCR and the amino acid-depleting
agent pegylated arginase I (BCT-100) in treating T-ALL
in the cancer microenvironment [23].
RNA interference (RNAi)-based therapeutics has emerged
for the treatment of various human diseases including
cancer [22,24]. Based on the efficacy of BCL11A siRNA
in inhibiting SUDHL6 cells [17], we hypothesized that
BCL11A siRNA plus VCR enhances inhibitory activity
in SUDHL6 cells. To the best of our knowledge, our
findings indicate for the first time that BCL11A siRNA
increases VCR-induced apoptosis in SUDHL6 cells.
Therefore, our study implies that the combination of
BCL11A siRNA transfection plus VCR is an efficacious




BCL11A-specific siRNA (sense: GAAUCUACUUAGAAAG
CGATTand antisense: UCGCUUUCUAAGUAGAUUCTT,
Chinese patent number: ZL 2011 1 0301731.6), which
targets domains in the third exon of the BCL11A gene
(ACCESSION NM_022893.3), [EMBL:AJ404611], and its
corresponding non-silencing negative control siRNA were
designed and synthesized by Shanghai GenePharma Co.,
Ltd. (Shanghai, China). RPMI 1640 and newborn calf serum
were purchased from Gibco (Gibco, Carlsbad CA, USA).
VCR was purchased from Shenzhen Main Luck Pharma-
ceuticals, Inc (Shenzhen, Guangdong, China).
Cell culture and transfection
The SUDHL6 cell line, which was derived from germinal
center B cell-like DLBCL, was kindly provided by Profes-
sor Ailin Guo from the Department of Pathology (Cornell
University, Ithaca, NY, USA). The cells were cultured inRPMI medium supplemented with 10% heat-inactivated
fetal calf serum at 37°C under 5% CO2 in a humidified
incubator. SUDHL6 cells in the exponential growth phase
were grown for 24 hours and then transfected using
HiPerFect (Qiagen, Valencia, CA, USA) according to the
manufacturer’s protocols. In addition, cells were trans-
fected with negative control siRNA. The total concentra-
tion of siRNA applied in every case was maintained
constant at 100 nM.
Assay of cell viability
For the quantitative determination of cellular proliferation
and viability, we performed the CCK8 assay. This assay
was performed after SUDHL6 cells were transfected with
BCL11A siRNA in combination with VCR (1 μM) at 24, 48
and 72 h. The cells were washed, counted and seeded at a
density of 4 × 105 cells/ml per well in 96-well plates. Six
hours later, BCL11A siRNA in combination with VCR was
added to the cells. At 48 and 72 h after transfection, CCK8
solution was added 4 h before the end of incubation. Cell
viability was measured with a spectrophotometer at an ab-
sorbance of 450 nm. The inhibition rates of cell growth
were calculated according to the following formula: inhib-
ition rate (%) = (1 ‐mean absorbance of treatment group/
mean absorbance of untreatedmentgroup) × 100%.
Assays of cell apoptosis
Transfected SUDHL6 cells were harvested after treatment.
Morphology was determined with Hoechst 33258 following
incubation for 72 h. Cells were washed with PBS three
times and then stained with 10 μl Hoechst33258 nuclear
dye (KeyGEN, Nanjing, China) for 10 min at 37°C. After
cells had been washed with PBS three times, images were
obtained with a fluorescence microscope (Leica, Germany).
Apoptosis assays were performed using annexin V-
fluorescein isothiocyanate (annexin V-FITC) and propi-
dium iodide (PI) (BD Pharmingen, San Jose, CA, USA)
according to the instructions of the manufacturer. Briefly,
cells were centrifuged, washed with cold PBS, and then re-
suspended in 500 μl binding buffer. FITC-conjugated
Annexin V (10 μl) and PI (10 μl) were added to each
sample, and the mixture was incubated at 4°C in the dark
for 5 min. The cells were then immediately subjected to
fluorescence-activated cell sorting (FACS) analysis (BD
FACS Calibur, Franklin Lakes, New Jersey, USA). The per-
centage of early and late apoptotic cells in each group was
determined.
Statistical analysis
Results are shown as the mean ± s.d. Statistical compari-
sons were made using ANOVA. Differences were deemed
significant for a real alpha of 0.05. All statistical analysis
was performed with SPSS 13.0.
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BCL11A is a Krüppel-like transcription factor that is closely
related to B cell proliferation and differentiation [6,8]. High
expression of BCL11A is thought to possibly be involved in
the genesis of B cell neoplasms [11,13-16]. We found that
downregulation of BCL11A expression by siRNA can
inhibit proliferation and induce apoptosis in SUDHL6 cells
[17]. Gene expression profiling of BCL11A siRNA-treated
SUDHL6 cells in our laboratory also highlighted that
BCL11A might be related to a variety of signaling
networks including apoptosis and the cell cycle (WH and
Gao Yangjun, unpublished data). In this study, consistent
with our previous report, BCL11A siRNA inhibited the
proliferation and growth of SUDHL6 cells [17]. These re-
sults suggest that oncogenic BCL11A may be a rational
therapeutic target in B cell lymphoma. Hence, of particular
interest is to observe whether BCL11A siRNA significantly
enhances the therapeutic efficacy of chemotherapeutic
drugs in B cell malignancy. Therefore, we attempted to
explore the combinatorial effects of BCL11A siRNA and a
chemotherapeutic agent (VCR).
Interestingly, our results demonstrated that cell viability
was more effectively reduced by BCL11A siRNA combined
withVCR in a time-dependent fashion (P <0.05) (Figure 1).
Furthermore, in order to identify the mechanism respon-
sible for this decline in cell viability, a morphology assay
was used. Our results showed significant apoptotic morph-
ology changes such as chromatin condensation and frag-
mentation at 72 h after transfection with BCL11A siRNA
in combination with VCR in SUDHL6 cells (Figure 2).



























Figure 1 The rate of inhibition of SUDHL6 cell growth as measured b
plus vincristine (VCR). SUDHL6 cell proliferation was determined by the C
according to the following formula: inhibition rate (%) = (1 - mean absorba
and the resulting values were plotted. The results represent mean values frPI double-positive cells at 72 h after transfection with
BCL11A siRNA in combination with VCR in SUDHL6
cells. The apoptosis rate of BCL11A siRNA combined with
VCR treatment was (71.46 ± 2.53)%, which was statisti-
cally significantly different compared with BCL11A
siRNA (39.64 ± 5.17)% or VCR (49.73 ± 6.74)% treatment
alone (P <0.05) (Figure 3). There was no significant differ-
ence compared with VCR and the negative control siRNA
plus VCR treatment (50.32 ± 6.18)%. Therefore, this study
showed that BCL11A siRNA in combination with VCR en-
hances apoptosis, thereby inhibiting the proliferation and
growth of SUDHL6 cells. These results indicate that there
is a potential therapeutic benefit for the combination of
BCL11A siRNA and VCR compared with BCL11A siRNA
or VCR alone.
These results are consistent with a related report that
showed that silencing the antiapoptotic protein Bfl-1 by
siRNA in DLBCL cell lines induced apoptosis and sensi-
tized those cells to apoptosis induced by chemotherapeu-
tic compounds such as doxorubicin, vincristine, cisplatin
and fludarabine [25].
SUDHL6 cells, which were chosen for this study, are
characterized by a t(14;18) chromosomal translocation
resulting in overexpression of the antiapoptotic protein
BCL-2. In SUDHL6 cells transfected with BCL11A
siRNA, we found that the apoptosis gene BIM (BCL2-
interacting mediator of cell death) was upregulated, and
the anti-apoptosis genes BCL-2 and MDM2 (murine
double minute 2) were downregulated (WH and Gao
Yangjun, unpublished data). A recent study has sug-
gested BCL11A deletion causes apoptosis in early B cellsP <0.05
y the CCK8 assay after combined treatment with BCL11A siRNA
CK8 assay. The inhibition rates for cell growth were calculated
nce of treatment group/mean absorbance of untreated group) × 100%,
om three independent experiments ± s.d.
Figure 2 The morphology effects from the combination of BCL11A siRNA plus vincristine in SUDHL6 cells at 72 hours. The nuclear
morphology of cells stained with Hoechst 33258 was analyzed by fluorescence microscopy (400×) at 72 h after transfection. Data are
representative microscopic images of three independent experiments. A) untreated cells; B) negative control siRNA; C) BCL11A siRNA;
D) vincristine; E) negative control siRNA plus vincristine; F) BCL11A siRNA plus vincristine.
Figure 3 The rate of apoptosis induced by the combination of BCL11A siRNA and vincristine in SUDHL6 cells at 72 hours. Apoptosis was
analyzed by annexin V-FITC/PI staining 72 h after treatment. Data are representative images of three independent experiments. A) untreated cells;
B) negative control siRNA; C) BCL11A siRNA; D) vincristine; E) negative control siRNA plus vincristine; F) BCL11A siRNA plus vincristine.
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xL, MDM2, and MDM4 [8].
Two research groups demonstrated that the small mol-
ecule ABT-737, a BCL-2 homology domain 3 mimetic, in
combination with VCR increased the apoptotic cell death
of leukemia cell lines [26,27]. Our previous studies and
other groups have suggested that downregulation of BCL-
2 expression by siRNA increases the sensitivity of human
tumor cells to chemotherapeutic drugs [28-30]. MDM2
negatively regulates the activity of the tumor suppressor
protein p53, thus having an anti-apoptotic role [31].
MDM2 inhibition by the antagonist nutlin-3 sensitizes
neoplasm cells to chemotherapy-induced apoptotic cell
death [32,33]. The mechanism of induced apoptosis
mediated by VCR is complex and involves protein ki-
nase signaling pathways [34]. Mitochondria also appear
to play a key role in this process [35]. Based on these
findings, we inferred that the BCL11A siRNA plus VCR-
induced apoptosis of SUDHL6 cells might be related to
the downregulation of BCL-2 and MDM2 and upregula-
tion of BIM. However, how BCL11A siRNA and VCR
are involved in enhancing the apoptotic process by
BCL-2, MDM2 and/or BIM needs further investigation.
Conclusions
We demonstrated that combined treatment with BCL11A
siRNA and VCR increases the inhibitory effects of in vitro cell
growth and apoptosis in SUDHL6 cells. Our study indicates
that the combination of BCL11A siRNA and VCR offers a
novel and potential therapeutic strategy for B cell malignancies.
However, further investigation of a wide range of B lymphoma
cell types and chemotherapeutic drugs and in vivo studies con-
firming the efficacy of this treatment paradigm are necessary.
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